About Tempest Therapeutics
Tempest is a clinical-stage biotechnology company advancing small molecules that combine both precision and immune-mediated mechanisms to modulate anti-tumor pathways. In addition to TPST-1495, the company is progressing TPST-1120, a second novel small molecule that selectively antagonizes the PPARα transcription factor. TPST-1120 has a two-pronged anti-cancer effect, inhibiting the growth of the tumors directly, as well as designated suppressive immune cell populations that prevent immune recognition and tumor rejection. TPST-1120 is currently being evaluated in a Phase 1a/1b study in patients with advanced solid malignancies.
Tempest is headquartered in South San Francisco and supported by notable healthcare investors Versant Ventures, F-Prime Capital, Quan Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Lyfe Capital and Rock Springs Capital Management. More information about Tempest can be found on the company’s website at www.tempesttx.com.